Atea Pharmaceuticals

Atea Pharmaceuticals

  • Founded: 2014
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin3
  • Therapy area: COVID-19
  • Drug types: INF
  • Lead product: AT-527
  • Product link:
  • Funding: $345M IPO Oct 2020

job board

Short description:

Nucleoside and nucleotide analogs to inhibit the viral RNA polymerase

Drug notes:

Also Clin2 hepatitis C; AT-752 Clin2 Dengue; undisclosed programs Clin0 COVID-19

Long description:

Atea Pharmaceuticals is developing oral direct-acting antiviral therapies. Single-stranded positive-sense RNA viruses, such as SARS-CoV-2, account for a large number of clinically serious global pathogens. To multiply in number, these viruses depend on an enzyme called RNA-dependent RNA polymerase. Atea is identifying oral inhibitors of this enzyme through the use of their purine nucleotide prodrug platform. The platform screens a large library of nucleoside and nucleotide analogs prodrugs that are uniquely active against RNA viruses.- Using their experience of developing antivirals, Atea is then enhancing the antiviral activity and selectivity through specific chemical modifications. Atea’s lead product candidate, AT-527, is being developed as a monotherapy for COVID-19.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy